Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bliss GVS Pharma reported its Q1 FY26 results, with standalone revenue from operations rising about 10% year-on-year to Rs 163.36 crore (from Rs 148.96 crore in Q1 FY25). Standalone net profit grew roughly 8% to Rs 21.05 crore, with basic EPS of Rs 2.00 versus Rs 1.85 a year ago. On a consolidated basis, revenue climbed to Rs 207.47 crore, while net profit jumped to Rs 44.36 crore from Rs 22.11 crore, more than doubling year-on-year. The company has deconsolidated its step-down subsidiary Greenlife Bliss Healthcare (sold 51% stake for USD 1.3 million) effective April 1, 2025, which impacts the consolidated comparability. Statutory auditors Kalyaniwalla & Mistry LLP issued an unmodified limited review report on both sets of results.
Results are largely in line-to-positive: consolidated earnings saw a sharp jump, though partly helped by the deconsolidation effect. Standalone performance shows steady single-digit growth, while finance costs have risen over fourfold year-on-year, which investors should watch. Overall, the clean audit report and EPS growth are supportive for shareholders.